MAP2K1 and B-cell chronic lymphocytic leukemia: More recently, in a large WES study investigating a CLL cohort of 538 cases, Landau and colleagues revealed an 8.7% mutation incidence in RAS-MAPK pathway genes, including KRAS and NRAS (4.1%), BRAF (3.7%) and MAP2K1 (2%).